Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

772
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
772
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

661
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
661
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

1.1K
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
1.1K
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

1.4K
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.4K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

585
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
585
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

889
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
889

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraoperative Therapeutic Plasma Exchange for Sensitized Heart Transplant Candidates.

Journal of clinical apheresis·2026
Same author

Lessons Learned from the HVAD Post-Approval Study Registry: Implications for Investigating Future Ventricular Assist Device Technology.

Journal of cardiac failure·2026
Same author

Beating heart transplantation: A single center's initial experience and propensity-matched analysis against national registry data.

JHLT open·2026
Same author

Three-year outcomes with the use of dual non-invasive rejection surveillance after heart transplantation.

JHLT open·2026
Same author

Donation After Circulatory Death Donors for Heart Transplantation: Does Center Volume Matter?

Journal of cardiac failure·2026
Same author

Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection: An Analysis of the Surveillance HeartCare Outcomes Registry.

JACC. Heart failure·2025

Related Experiment Video

Updated: Apr 5, 2026

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.5K

Right ventricular failure after left ventricular assist devices.

Brent C Lampert1, Jeffrey J Teuteberg2

  • 1Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|August 13, 2015
PubMed
Summary

Right ventricular failure (RVF) is a common complication after left ventricular assist device (LVAD) implantation, impacting patient outcomes. This review explores RVF predictors, management, and chronic challenges post-LVAD.

Keywords:
RVF predictorsleft ventricular assist deviceperi-operative mortalityright ventricular failurerisk models

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K
Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

160

Related Experiment Videos

Last Updated: Apr 5, 2026

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.5K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K
Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

160

Area of Science:

  • Cardiovascular Medicine
  • Medical Devices
  • Surgical Complications

Background:

  • Advanced systolic dysfunction often coexists with right ventricular (RV) dysfunction in patients evaluated for left ventricular assist devices (LVADs).
  • Right ventricular failure (RVF) is a frequent complication following LVAD implantation, associated with increased mortality, prolonged hospitalization, and reduced quality of life.

Purpose of the Study:

  • To review the anatomical and physiological changes of the RV in the context of LVAD support.
  • To discuss biochemical, echocardiographic, and hemodynamic predictors of RVF in LVAD patients.
  • To outline strategies for the prevention and management of RVF, including chronic RVF.

Main Methods:

  • Review of existing literature on RV anatomy, physiology, and RVF in LVAD patients.
  • Discussion of proposed mechanisms, risk factors, and predictive markers for RVF.
  • Synthesis of current and potential management strategies for acute and chronic RVF.

Main Results:

  • RVF significantly complicates LVAD therapy, leading to adverse clinical outcomes.
  • Multiple predictors (biochemical, echocardiographic, hemodynamic) for RVF have been identified.
  • Limited effective medical and surgical treatments exist for RVF, highlighting the need for better strategies.

Conclusions:

  • Understanding RV physiology under LVAD support is crucial for predicting and managing RVF.
  • Early identification and proactive management of RVF are essential to improve patient prognosis.
  • Further research is needed to address the challenges of chronic RVF after LVAD placement.